Inhibikase Therapeutics IKT 深 滬
等待開盤 12-18 09:30:00 美东时间
1.575
-0.025
-1.56%
華盛通- 最 高1.64
- 今 開1.59
- 成交量 18.79万股
- 最 低 1.55
- 昨 收 1.60
- 總市值 1.17亿
- 52周最高 3.49
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 1.33
- 委 比 -53.05%
- 總股本 7434.15万
- 歷史最高 70.80
- 量 比 0.69
- 振 幅 5.63%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.
12-11 22:57
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. On November 20...
11-22 05:48
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share
Clinical-stage pharmaceutical company Inhibikase Therapeutics (IKT) announced the pricing of its underwritten public offering, anticipating gross proceeds of approximately $100.0 million. The company ...
11-21 16:09
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
11-21 05:06
Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Global Phase 3 Trial And Is Expected To Begin In Q1 2026
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial
11-21 05:04
Inhibikase Therapeutics Q3 EPS $(0.13), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the same period last year.
11-15 05:03
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics, Inc. has appointed Timothy Pigot as Chief Commercial and Strategy Officer. Pigot, with over three decades of experience in pharmaceuticals, joins the company as it advances its PAH treatment candidate IKT-001 toward late-stage trials. He previously led commercial strategies at Aerovate Therapeutics and MyoKardia. Inhibikase focuses on developing therapies for cardiopulmonary diseases, particularly PAH, which affects aroun...
08-19 12:00
Inhibikase Therapeutics GAAP EPS of -$0.11
Inhibikase Therapeutics press release (NASDAQ:IKT): Q2 GAAP EPS of -$0.11. As of June 30, 2025, cash, cash equivalents and marketable securities were $87.7 million as compared to $97.5 million as of D...
08-15 18:38
Inhibikase Therapeutics To Initiate Phase 2b Study Of IKT-001 In PAH In H2 2025
-SEC Filing
08-15 05:06
